Merrimack Pharma (MACK) Drops Lower Following ONIVYDE Approval; Will Include 'Boxed Warning'
Tweet Send to a Friend
Merrimack (Nasdaq: MACK) shares are down over 21 percent with heavy volume Thursday afternoon after the company announced that ONIVYDE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


